Adam S. Kibel, MD, presented “Prostate Cancer Detection Biomarkers, MRI” during the 44th Annual Ralph E. Hopkins Urology Seminar on February 7, 2025, in Jackson Hole, Wyoming.
This content is available free to the GRU Community. Login or create an account to view it.
How to cite: Kibel, Adam S. “Prostate Cancer Detection Biomarkers, MRI.” February 7, 2025. Accessed Mar 2025. https://grandroundsinurology.com/prostate-cancer-detection-biomarkers-mri/
Prostate Cancer Detection Biomarkers, MRI – Summary
Adam S. Kibel, MD, delves into contemporary strategies for prostate cancer detection. In this 18-minute presentation, Dr. Kibel emphasizes the role of MRI and biomarkers in refining diagnostic accuracy.
Highlighting the limitations of PSA alone, Dr. Kibel presents an evolving paradigm where MRI-guided biopsies outperform traditional systematic biopsies in identifying clinically significant cancers. Large trials such as PRECISION and PROMIS demonstrate MRI’s superior sensitivity and specificity.
Dr. Kibel shares that serum- and urine-based tests enhance diagnostic precision, including the PSA Health Index, 4KScore, and PCA3. Novel urine-based assays like EPI and MyProstateScore 2.0 further refine biopsy decisions, leveraging genetic markers to assess cancer risk. A meta-analysis comparing multiple biomarkers underscores the absence of a single definitive test, reinforcing the need for personalized diagnostic pathways.
Dr. Kibel underscores the importance of clinical judgment in test selection, cautioning against excessive testing that generates conflicting results. He emphasizes balancing early detection with minimizing overtreatment and advocates a streamlined, evidence-based approach to prostate cancer screening.
About The 44th Annual Ralph E. Hopkins Urology Seminar:
The Ralph E. Hopkins Urology Seminar is a multi-day meeting focused on training urologists in the latest in assessing, diagnosing, and treating urologic conditions in the clinical setting. Updates are provided on urologic cancers, stone disease, urologic reconstruction, female urology, infertility, sexual function, emerging surgical techniques, and general urology. The 44th iteration of the meeting took place from February 5th to February 8th, 2025, in Jackson Hole, Wyoming.
For further educational activities from this conference, visit our collection page.
ABOUT THE AUTHOR
Adam S. Kibel, MD, is the DiNovi Family Distinguished Chair of Urology at Brigham and Women’s Hospital and Dana-Farber Brigham and Women’s Cancer Center in Boston, Massachusetts. Dr. Kibel is also the Elliott Carr Cutler Professor of Surgery at Harvard Medical School, and Chairman of the Harvard Urology Residency Program. His clinical interests include genetics of prostate cancer, minimally-invasive surgical treatments for urologic cancers, and robotic surgery for urologic cancers.
Dr. Kibel received his undergraduate and medical degrees from Cornell University Medical School. Dr. Kibel completed his urology residency at the Harvard Urology Program and his fellowship at the Brady Urologic Institute at John Hopkins.
Dr. Kibel has been listed as one of America’s Top Doctors by Castle Connolly and was named a top urologist by Boston magazine for his work on minimally invasive treatments for urologic cancers. Dr. Kibel has authored over 250 peer-reviewed publications on his research, with topics including the identification of molecular markers of urologic tumors, adjuvant and neoadjuvant approaches to treatment of aggressive disease and improved imaging of patients with urologic malignancies. Dr. Kibel’s research has been supported by the National Cancer Institute, American Cancer Society, American College of Surgeons, and the American Foundation for Urologic Disease.
